KRAS
Entity.
- Evidence
- 429 documents · 172 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 14 Oct 2026
- Measured
- 10% of mentions say something specific about it; the rest only name it
- As of
- 15 Oct 2026
Where this comes from
- Cancer Cell · 2026-10-12 · Hitting KRAS G12D without the gut punch: Can immunotherapy make it last? (opens the source in a new tab)
- PLoS Comput Biol · 2026-10-09 · Hyper-mutational processes provide a head-start for weak cancer drivers: Explaining atypical KRAS variants. (opens the source in a new tab)
- Fierce Pharma · 2026-10-09 · FDA’s Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data (opens the source in a new tab)
- Bioorg Chem · 2026-10-08 · Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer. (opens the source in a new tab)
- medRxiv Oncology · 2026-10-07 · Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic r… (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-07 · Lipid acyl chain remodeling governs KRAS nanoclustering and oncogenic functions through membrane composition control (opens the source in a new tab)
- MedComm (2020) · 2026-10-06 · KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. (opens the source in a new tab)
- Arq Bras Cir Dig · 2026-10-05 · Association between KRAS gene mutation and clinicopathological factors in patients with metastatic colorectal cancer. (opens the source in a new tab)
- J Thromb Haemost · 2026-10-03 · KRAS Mutation and Venous Thromboembolism Risk in Colorectal Cancer: A Danish Population-Based Cohort Study. (opens the source in a new tab)